# Table of Contents

**January 1, 2016 • Volume 22 • Number 1**

## Highlights of This Issue 1

### SPECIAL FEATURES

#### CCR Translations

3 Right-Sizing Adjuvant and Neoadjuvant Clinical Trials in Breast Cancer

Donald A. Berry

See related article, p. 26

6 Is It Better to Be Rich or Relaxed? Sociobiology Meets Bone Marrow Transplant

Lucie M. Turcotte and Michael R. Verneris

See related article, p. 69

#### CCR New Strategies

9 New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy

Uwe Haberkorn, Matthias Eder, Klaus Kopka, John W. Babich, and Michael Eisenhut

#### Molecular Pathways

16 Molecular Pathways: IDH2 Mutations—Co-opting Cellular Metabolism for Malignant Transformation

Eytan M. Stein

#### Review

20 From DNA Damage to Nucleic Acid Sensing: A Strategy to Enhance Radiation Therapy

Liufu Deng, Hua Liang, Sherry Fu, Ralph R. Weichselbaum, and Yang-Xin Fu

## CANCER THERAPY: CLINICAL

26 Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer

Christos Hatzis, W. Fraser Symmans, Ya Zhang, Rebekah E. Gould, Stacy L. Moulder, Kelly K. Hunt, Mayya Abu-Khalaf, Erin W. Hoistatter, Donald Lannin, Anes B. Chaggar, and Lajos Pusztai

See related commentary, p. 3

34 Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma


44 A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer

Martin Schlumberger, Barbara Janzab, Maria E. Cabanillas, Bruce Robinson, Furio Pacini, Douglas W. Ball, Judith McCaffrey, Kate Newbold, Roger Allison, Renato G. Martins, Lisa F. Licitra, Manisha H. Shah, Donald Bodenner, Rossella Elisei, Lynn Burmeister, Yasuhiro Funahashi, Min Ren, James P. O’Brien, and Steven I. Sherman

54 An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy

Masanori Noguchi, Kazumasa Matsumoto, Hirotugu Uemura, Gaku Arai, Masatoshi Eto, Seiji Naito, Chikara Ohyama, Yasutomo Nasu, Masatoshi Tanaka, Fukuko Moriya, Shigetaka Suekane, Satoke Matsueda, Nobukazu Komatsu, Tetsuro Sasada, Akira Yamada, Tatsuyuki Kukuma, and Koigo Itoh

61 A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma

Andrew H. Ko, Tanios Bekaii-Saab, Jessica Van Zifelle, Olga M. Mirozeva, Nancy M. Joseph, AmirAli Talasaz, Peter Kuhn, Margaret A. Tempero, Eric A. Collisson, R. Kate Kelley, Alan P. Venook, Elizabeth Dito, Anna Ong, Sharvina Ziyeh, Ryan Courtin, Regina Linetskaya, Sanaa Tahiri, and W. Michael Korn

## PERSONALIZED MEDICINE AND IMAGING

69 Low Socioeconomic Status, Adverse Gene Expression Profiles, and Clinical Outcomes in Hematopoietic Stem Cell Transplant Recipients

Jennifer M. Knight, J. Douglas Rizzio, Brent R. Logan, Tao Wang, Jesus M.G. Arevalo, Jeffrey Ma, and Steve W. Cole

See related commentary, p. 6
79 Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms

CANCER THERAPY: PRECLINICAL

86 Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
Martin Skarzynski, Carsten U. Niemann, Yuh Shan Lee, Sabrina Martyz, Irina Matic, Dalia Salem, Maryalice Sterler-Stevenson, Gerald E. Marti, Katherine R. Calvo, Constance Yuan, Janet Valdez, Susan Soto, Mohammed Z.H. Farooqui, Sarah E.M. Herman, and Adrian Wiestner

96 Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors
Lukas J.A.C. Hawinkels, Amaya Garcia de Vinuesa, Madelon Paauwe, Marianna Kruithof-de Julio, Eliza Wiercinska, Evangelia Pardali, Laura Mezzanotte, Stijn Keereweer, Tanya M. Braumuller, Renier C. Heijkants, Jos Jonkers, Clemens W. L€owik, Marie-Jos/C19e Goumans, Timo L. ten Hagen, and Peter ten Dijke

107 Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer
Andreas Varkaris, Paul G. Corn, Nila U. Parikh, Eleni Efstathiou, Jian H. Song, Yu-Chen Lee, Ana Aparicio, Anh G. Hoang, Sanchaika Gaur, Lynnelle Thorpe, Sankar N. Maity, Menashe Bar Eli, Bogdan A. Czerniak, Yiping Shao, Mian Alauddin, Sue-Hwa Lin, Christopher J. Logothetis, and Gary E. Gallick

BIOLOGY OF HUMAN TUMORS

146 Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer
Siker Kimbung, Ida Johansson, Anna Danielsson, Srinivas Voela, Suzanne Eghazzi Bege, Marianne Frostvik Stol, Lambert Skoog, Lena Carlsson, Zakaria Einbeigi, Elisabet Lidbrink, Barbro Lindholm, Niklas Loman, Per-Olof Malmström, Martin Söderberg, Thomas M. Walz, Märtén Fernö, Thomas Hatschek, and Ingrid Hedenfalk in collaboration with the TEX study group

158 CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer
Bruno C. Leclerc, Roxanne Charlebois, Guillaume Chouinard, Bertrand Allard, Sandra Pommey, Fred Saad, and John Stagg

167 Antigen Selection Shapes the T-cell Repertoire in Chronic Lymphocytic Leukemia
Anna Vardi, Andreas Agathangelidis, Evangelia Stalika, Maria Karypidou, Alexandra Sioriota, Achilles Anagnostopoulos, Richard Rosenquist, Anastasia Hadadimitriou, Paolo Ghia, Lesley-Ann Sutton, and Kostas Stamatopoulos

175 PKCc Attenuates Jagged–1–Mediated Notch Signaling in ErbB-2–Positive Breast Cancer to Reverse Trastuzumab Resistance

187 ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy
Zheng Chen, Albert E. Teo, and Nami McCarty

200 Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS)
Florian Posch, Johannes Thaler, Gerhard-Johann Zlabinger, Oliver Königspürgge, Silvia Koder, Christoph Zielinski, Ingrid Pabinger, and Cihan Ay
Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma
Irena Misiewicz-Krzeminska, María E. Sarasquete, Carolina Vicente-Dueñas, Patryk Krzeminski, Katarzyna Wiktorska, Luis Antonio Corchete, Dalia Quwaider, Elizabeta A. Rojas, Rocío Corral, Ana A. Martín, Fernando Escalante, Abelardo Bárez, Juan Luis García, Isidro Sánchez-García, Ramón García-Sanz, Jesús F. San Miguel, and Norma C. Gutiérrez

Prognostic and Chemotherapy Predictive Value of Gene-Expression Phenotypes in Primary Lung Adenocarcinoma
Markus Ringnér, Göran Jönsson, and Johan Staaf

EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer

Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening

Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor
Anna Karpathakis, Harpreet Dibra, Chistodoulos Pipinikas, Andrew Feber, Tiffany Morris, Joshua Francis, Dalmane Oukrif, Dalvinder Mandair, Marios Pericleous, Mullan Mohmaduvesh, Stefano Serra, Olagunju Ogunbiyi, Marco Novelli, TuVinh Luong, Sylvia L. Asa, Matthew Kulke, Christos Toutoumpakis, Tim Meyer, Martyn Caplin, Matthew Meyerson, Stephan Beck, and Christina Thirlwell

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Teresa Helseth, Sheryl Elkin, Elisa Arthur, Brett N. Tomson, Jennifer Carter, and Razelle Kurzrock

LETTERS TO THE EDITOR

Neoadjuvant as Future for Drug Development in Breast Cancer—Letter
Marc Buyse, Tomasz Burzykowski, and Everardo D. Saad

Neoadjuvant as Future for Drug Development in Breast Cancer—Response
Angela DeMichele, Douglas Yee, Melissa Paoloni, Don Berry, and Laura J. Esserman, on behalf of the I-SPY2 Investigators

RETRACTION

Retraction: Suppression of N-Methyl-N-nitrosourea/Testosterone-Induced Rat Prostate Cancer Growth by Celecoxib: Effects on Cyclooxygenase-2, Cell Cycle Regulation, and Apoptosis Mechanism(s)
Teresa Helseth, Sheryl Elkin, Elisa Arthur, Brett N. Tomson, Jennifer Carter, and Razelle Kurzrock
ABOUT THE COVER

The cover shows a section from a patient-derived xenograft of prostate cancer grown in mice treated with the MET/VEGFR-2 inhibitor, cabozantinib. Immunohistochemical staining shows an islet of viable tumor cells surrounding a VEGFR-2-negative blood vessel, with apoptotic cells surrounding the islet. For details, see the article by Varkaris and colleagues on page 107 of this issue.